摘要
目的设计合成一类以(S)-2-羟基-3-甲氧基-33,-二苯基丙酸为母体的新型内皮素受体拮抗剂并对其生物活性进行研究。方法二苯甲酮和氯乙酸甲酯在甲醇钠存在下发生Darzen反应,再经过开环反应和水解反应得到α-羟基酸,α-羟基酸经拆分得到手性羟基丙酸中间体,该中间体与硝基吡啶系列化合物发生双分子亲核取代反应制得目标化合物。通过大鼠离体动脉环实验测定目标化合物对内皮素受体的拮抗作用。结果合成了5个未见报道的新化合物,化合物的结构经1H-NMR谱确证,并且对它们的比旋光度进行了测定。结论大鼠离体动脉环实验结果显示目标化合物具有明显的内皮素受体拮抗作用。
Five pyridine-bearing endothelin receptor antagonists based on ambrisentan as structural template were designed and synthesized.The synthetic procedure started from benzophenone,which underwent Darzens condensation to afford an epoxide.The epoxide was opened when treated with p-toluenesulfonic acid in refluxing methanol to give methyl 3,3-diphenyl-2-hydroxy-3-methoxypropionate,which was saponified to yield the corresponding acid followed by revolution with(S)-1-(p-chlorophenyl) ethylamine to furnish the enantiomerically pure(S)-3,3-diphenyl-2-hydroxy-3-methoxypropionic acid in the form of an aminium salt.Coupling of the aminium salt of this enantiomerically pure hydroxyl carboxylic acid and the pyridine-bearing electrophiles in the presence of lithium amide furnished the desired title compounds,(S)-3,3-diphenyl-3-methoxy-2-(substituted pyridinyloxy)propionic acids.Biological activity evaluated with rat aortic ring relaxation model revealed that the potency order of endothelin receptor antagonism was 9b9a10b9c10a,indicating that more substituents at m-positions more potent were their endothelin receptor antagonism.
出处
《中国药物化学杂志》
CAS
CSCD
2011年第3期199-203,共5页
Chinese Journal of Medicinal Chemistry
基金
"重大新药创制"科技重大专项大平台子课题(2009ZX09301-008-P-05)
关键词
内皮素受体拮抗剂
合成
拆分
肺动脉高压
endothelin receptor antagonists
synthesis
revolution
pulmonary arterial hypertension